Short Overview

EVARREST™ Fibrin Sealant Patch innovation offers superior hemostatic efficacy on the first attempt.^*1-4 Hemostasis is achieved with EVARREST™ Fibrin Sealant Patch when the formed fibrin clot integrates with the patch component and adheres to the wound surface, thus also providing a physical barrier to bleeding.⁵ 

*EVARREST™ demonstrated hemostatic superiority across 4 clinical trials. Trial 1: Soft Tissue hemorrhage: Per protocol efficacy measured at n=87, 100% vs 53.3% for Surgicel Δ 46.7% P<0.0001; (ITT population=90). Trial 2: Normal and Abnormal liver resection hemorrhage: Per protocol efficacy measured at n=77, 94.3% vs 28.6% for conventional adjunctive methods Δ 65.7% P<0.001; (ITT population=84). Trial 3: Anatomic and nonanatomic liver resection hemorrhage: Per protocol efficacy measured at n=93, 97.9% vs 44.4% for conventional adjunctive methods Δ 53.5% P<.0001; (ITT population=102). Trial 4: Aortic reconstruction: Per protocol efficacy measured at n=141, 78.8% vs 46.7% for Tachosil Δ 32.1% P<0.0001; (ITT population=156).

References:
1. Fischer CP, et al. Clinical Study Report 400-07-002. 20 November 2009.
2. Koea JB, Batiller J, Patel B, et al. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB. 2013;15(1):61-70.
3. Garden, OJ, et al. Clinical Study Report BIOS-13-005. 13 November 2014.
4. Kocharian, R et al. Clinical Study Report BIOS-13-004. 03 December 2015.
5. EVARREST™ Fibrin Sealant Patch Prescribing Information. Ethicon, Inc.